EDRH
NVCT icon

Edmond de Rothschild Holding’s Nuvectis Pharma NVCT Stock Holding History

Edmond de Rothschild Holding’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,170
Closed -$117K – 628
2026
Q1 		$117K Hold
15,170
– – ﹤0.01% 406
2025
Q4 		$115K Hold
15,170
– – ﹤0.01% 420
2025
Q3 		$91.3K Hold
15,170
– – ﹤0.01% 434
2025
Q2 		$113K Hold
15,170
– – ﹤0.01% 409
2025
Q1 		$148K Hold
15,170
– – ﹤0.01% 402
2024
Q4 		$82.1K Sell
15,170
-4,000
-21% -$25.1K ﹤0.01% 464
2024
Q3 		$121K Hold
19,170
– – ﹤0.01% 458
2024
Q2 		$121K Hold
19,170
– – ﹤0.01% 471
2024
Q1 		$157K Hold
19,170
– – ﹤0.01% 447
2023
Q4 		$160K Buy
+19,170
New +$171K ﹤0.01% 454
2023
Q3 		– Sell
-22,820
Closed -$364K – 738
2023
Q2 		$364K Sell
22,820
-1,750
-7% -$27.9K 0.01% 400
2023
Q1 		$322K Buy
+24,570
New +$249K 0.01% 399

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Edmond de Rothschild Holding's NVCT Position: Q2 2026 in Review

Edmond de Rothschild Holding sold out of Nuvectis Pharma (NVCT) in Q2 2026, closing a stake of 15,170 shares — an estimated $117K sold.

Edmond de Rothschild Holding first reported a position in NVCT in Q1 2023 and held it in 12 quarters. The position peaked at $364K in Q2 2023. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Edmond de Rothschild Holding reported no remaining Nuvectis Pharma position as of Q2 2026 after selling out during the quarter.
  • Edmond de Rothschild Holding sold 15,170 Nuvectis Pharma shares in Q2 2026, an estimated $117K.
  • Edmond de Rothschild Holding first reported a position in Nuvectis Pharma in Q1 2023 and held it in 12 quarters.
  • Edmond de Rothschild Holding's Nuvectis Pharma position peaked at $364K in Q2 2023.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2026, filed 10 Aug 2026.